Related Experiment Video
Updated: May 28, 2026
09:48
An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
Published on: September 12, 2019
[Clinicopathological study of retroperitoneal sarcoma]
Ryo Yamashita1, Kentaro Muraoka, Masato Matsuzaki
1Division of Urology, Shizuoka Cancer Center.
Nihon Hinyokika Gakkai Zasshi. the Japanese Journal of Urology
|October 4, 2011
Summary
Surgery for retroperitoneal sarcoma has a high rate of local recurrence. Multimodal treatments including chemotherapy and radiotherapy are needed to improve outcomes for patients with retroperitoneal sarcoma.
Area of Science:
- Oncology
- Surgical Oncology
- Pathology
Context:
- Retroperitoneal sarcomas are rare and challenging tumors.
- Surgical resection is the primary treatment modality.
- Understanding recurrence patterns is crucial for improving patient survival.
Purpose:
- To retrospectively analyze patient characteristics, pathological findings, and recurrence patterns after surgery for retroperitoneal sarcoma.
- To evaluate recurrence-free survival following surgical intervention.
Summary:
- Nine patients with retroperitoneal sarcoma underwent surgery, with en-bloc resection achieved in eight.
- The most common diagnoses were dedifferentiated liposarcoma (7 cases) and leiomyosarcoma (2 cases).
- Five patients experienced local recurrence, with no distant metastases preceding local recurrence. Median time to local recurrence was 13 months.
Impact:
- Surgery alone for retroperitoneal sarcoma is associated with a high rate of local recurrence.
- Multimodal treatment strategies incorporating chemotherapy and radiotherapy are necessary to reduce local recurrence rates.
- Further prospective studies are required to establish optimal multimodal treatment protocols.
